RxSight, Inc. (RXST) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

RxSight, Inc. (RXST) Healthcare & Pipeline Overview

RxSight, Inc. develops and commercializes the RxSight system, featuring light adjustable intraocular lenses (LALs) and a light delivery device, enabling doctors to customize vision correction after cataract surgery. The company serves cataract surgeons in the United States and internationally, offering a novel approach to optimizing visual acuity post-surgery.

What Is the Investment Thesis for RXST?

RxSight presents a notable research candidate within the medical device sector, driven by its innovative LAL technology and the growing demand for advanced cataract surgery solutions. The company's revenue growth is tied to increased adoption of the RxSight system by cataract surgeons, with a gross margin of 77.0% indicating strong profitability potential as sales scale. Key catalysts include continued expansion of the installed base of LDDs and increasing awareness among patients and surgeons. However, the company's negative profit margin (-36.6%) highlights the need for efficient scaling and cost management. The stock's beta of 1.21 suggests higher volatility compared to the market. Investors should monitor the company's ability to achieve profitability, expand its market share, and maintain its technological advantage. The current market capitalization is $0.30B.

Based on FMP financials and quantitative analysis

RXST Key Highlights

RxSight's innovative Light Adjustable Lens (LAL) technology offers a unique approach to post-cataract surgery vision correction.

• The company's gross margin of 77.0% indicates strong potential for profitability as sales volume increases.
• RxSight's RxSight system includes the Light Delivery Device (LDD), an office-based treatment that customizes the LAL.
• The company serves cataract surgeons in the United States and internationally, with opportunities for geographic expansion.
• RxSight's market capitalization is $0.30B, reflecting investor valuation of its growth potential.

Who Are RXST's Competitors?

RXST is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RXST's Key Strengths?

Innovative Light Adjustable Lens (LAL) technology.

• Ability to customize vision correction after cataract surgery.
• Strong gross margin of 77.0%.
• Growing installed base of Light Delivery Devices (LDDs).

What Are RXST's Weaknesses?

Negative profit margin (-36.6%).

• Reliance on adoption by cataract surgeons.
• Limited market awareness compared to established players.
• Need for ongoing training and support for surgeons.

What Could Drive RXST Stock Higher?

Increasing adoption of the Light Adjustable Lens (LAL) by cataract surgeons.

• Expansion of the installed base of Light Delivery Devices (LDDs).
• Publication of clinical data supporting the efficacy of the RxSight system.
• Regulatory approvals in new international markets.

What Are the Key Risks for RXST?

Financial-distress signal — its Altman Z-Score of -0.20 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-17.4%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Competition from established IOL manufacturers.
• Changes in reimbursement policies for cataract surgery.
• Need for ongoing training and support for surgeons.
• Economic downturn affecting patient demand for premium lenses.

What Are the Growth Opportunities for RXST?

• Expansion of LDD Installed Base: A significant growth opportunity lies in increasing the installed base of Light Delivery Devices (LDDs) in ophthalmology practices. Each new LDD placement expands the reach of RxSight's technology and drives recurring revenue through LAL sales. The market size for cataract surgery is substantial, with millions of procedures performed annually worldwide. Timeline: Ongoing, with continued sales and marketing efforts targeting ophthalmology practices. Competitive Advantage: RxSight's LDD is proprietary and essential for utilizing the LAL, creating a captive market for its lenses.
• Increased LAL Adoption Rate: Driving higher adoption rates of the Light Adjustable Lens (LAL) among cataract surgeons is another key growth driver. This involves educating surgeons on the benefits of the LAL, providing training and support, and demonstrating improved patient outcomes. The market potential is significant, as the LAL offers a premium solution for patients seeking optimized vision correction. Timeline: Ongoing, with continuous efforts to promote the LAL and showcase its advantages. Competitive Advantage: The LAL's unique adjustability feature provides a distinct advantage over traditional IOLs.
• Geographic Expansion: Expanding into new geographic markets represents a substantial growth opportunity for RxSight. This includes obtaining regulatory approvals in key international markets and establishing distribution networks to reach cataract surgeons globally. The global cataract surgery market is large and growing, offering ample opportunities for RxSight to expand its footprint. Timeline: Ongoing, with phased expansion into select international markets. Competitive Advantage: RxSight's technology has the potential to be adopted globally, providing a competitive edge in new markets.
• Strategic Partnerships: Forming strategic partnerships with ophthalmology groups and hospitals can accelerate the adoption of RxSight's technology. These partnerships can provide access to a wider patient base and streamline the integration of the RxSight system into clinical practice. The market for strategic alliances in the medical device industry is active, with companies seeking to expand their reach and market share. Timeline: Ongoing, with continuous efforts to establish strategic partnerships. Competitive Advantage: Strategic partnerships can enhance RxSight's market presence and accelerate its growth trajectory.
• Technological Advancements: Continued investment in research and development to enhance the RxSight system and develop new applications for the LAL technology is crucial for long-term growth. This includes exploring new materials, improving the LDD, and expanding the range of vision correction options. The market for advanced ophthalmic technologies is constantly evolving, with ongoing innovations in lens design and surgical techniques. Timeline: Ongoing, with continuous R&D efforts to maintain a competitive edge. Competitive Advantage: RxSight's commitment to innovation can solidify its position as a leader in vision correction technology.

What Are RXST's Competitive Advantages?

• Proprietary Technology: RxSight's Light Adjustable Lens (LAL) technology is patented and offers a unique feature of post-operative adjustability.
• Installed Base: The installed base of Light Delivery Devices (LDDs) creates a captive market for LAL sales.
• Clinical Data: Strong clinical data supports the efficacy and safety of the RxSight system, building trust among surgeons.
• First-Mover Advantage: RxSight was among the first to commercialize an adjustable IOL, giving it a head start in the market.

What Does RXST Do?

RxSight, Inc., founded in 1997 and headquartered in Aliso Viejo, California, is a medical technology company focused on transforming the cataract surgery experience. Originally incorporated as Calhoun Vision, Inc., the company rebranded as RxSight, Inc. in February 2017 to reflect its commitment to vision correction. RxSight develops, manufactures, and markets the RxSight system, which includes the Light Adjustable Lens (LAL) and the Light Delivery Device (LDD). The LAL is an intraocular lens implanted during cataract surgery that can be adjusted non-invasively after implantation. The LDD is an office-based device that delivers UV light to modify the LAL, allowing doctors to customize and optimize a patient's vision. This system allows for precise vision correction, addressing common post-cataract surgery visual errors such as astigmatism and nearsightedness. RxSight primarily serves cataract surgeons and their patients, offering a technology that aims to improve visual outcomes and patient satisfaction following cataract surgery. The company's geographic focus includes the United States and international markets, with ongoing efforts to expand its reach and adoption of the RxSight system.

What Products and Services Does RXST Offer?

• Develops and manufactures light adjustable intraocular lenses (LALs) for cataract surgery.
• Offers the RxSight system, which includes the LAL and a light delivery device (LDD).
• Enables doctors to customize and enhance patients' vision after cataract surgery.
• Provides an office-based light treatment device (LDD) to modify the LAL.
• Serves cataract surgeons in the United States and internationally.
• Offers a technology that aims to improve visual outcomes and patient satisfaction following cataract surgery.

How Does RXST Make Money?

• Sells Light Adjustable Lenses (LALs) to cataract surgeons.
• Sells Light Delivery Devices (LDDs) to ophthalmology practices.
• Generates revenue from the initial sale of LDDs and recurring revenue from LAL sales.
• Provides training and support services to surgeons using the RxSight system.

What Industry Does RXST Operate In?

RxSight operates within the medical device industry, specifically targeting the cataract surgery market. The market is characterized by technological advancements aimed at improving surgical outcomes and patient satisfaction. RxSight's LAL technology differentiates it from traditional intraocular lenses by offering post-operative adjustability. The competitive landscape includes established players offering standard IOLs and emerging companies developing advanced surgical technologies. The aging global population and increasing prevalence of cataracts drive demand for cataract surgery, presenting growth opportunities for companies like RxSight.

Who Are RXST's Key Customers?

• Cataract surgeons in private practices.
• Ophthalmology groups and clinics.
• Hospitals with ophthalmology departments.
• Patients undergoing cataract surgery seeking advanced vision correction.

RxSight, Inc. (RXST) Valuation Context

Valued at $255M, RXST is classified as a micro-cap stock. Relative to its peer group, RXST's quantitative score of 20/100 is below the peer average of 72/100.

RXST Revenue & Earnings Trend

In Q2 2026, RXST generated $33.7M in top-line revenue, marking a sequential increase of 9.2%. The company recorded a net loss of $12.1M, with diluted EPS of $-0.29. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, RXST averaged $-0.28 in diluted EPS.

Company Profile

RxSight, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Aliso Viejo, US. The company is led by CEO Aziz Mottiwala. RXST has traded publicly since 2021.

Return on equity for RxSight, Inc. stands at -17.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -13.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -16.0%, the inverse of the P/E and a quick read on earnings relative to price.

RxSight, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.20 places it in the distress zone, a signal of elevated financial risk.

RxSight, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 11.5% above estimates on average.

Wall Street analysts project RxSight, Inc. revenue of about $143.1M for fiscal 2026, with EPS near $-1.05. The estimate reflects 7 contributing analysts.

RXST Financials

RXST Latest News

RXST Analyst Consensus

RXST MoonshotScore

RxSight, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources